Rhythm Pharmaceuticals (RYTM) Gross Margin (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Gross Margin data on file, last reported at 88.09% in Q1 2026.

• On a quarterly basis, Gross Margin fell 75.0% year-over-year to 88.09% in Q1 2026; TTM through Mar 2026 was 89.41%, a 21.0% decrease from a year earlier, with the FY2025 full-year figure at 89.73%, changed 0.0% from the prior year.
• Gross Margin for Q1 2026 stood at 88.09%, down from 91.61% in the prior quarter.
• Over the last five years, Gross Margin for RYTM reached as high as 112.77% in Q4 2022 and fell as low as 84.65% in Q1 2022.
• Historically, Gross Margin has averaged 90.5% across 5 years, with a median of 88.85% in 2025.
• Across the five-year window, Gross Margin soared 4583 bps in 2022 and plunged 2611 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 112.77% in 2022, then dropped by 23 bps to 86.66% in 2023, then gained by 5 bps to 90.95% in 2024, then increased by 1 bps to 91.61% in 2025, then retreated by 4 bps to 88.09% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 88.09% in Q1 2026, 91.61% in Q4 2025, and 89.28% in Q3 2025.